Cost-Effectiveness Analysis of Afatinib Versus Gefitinib in Egfr-Mutated Population with Advanced Non-Small-Cell Lung Cancer in France
Abstract
Authors
G de Pouvourville L Luciani K Le Lay P PO J Bennouna M Perol D Moro-Sibilot A Vergnengre C Chouaid